Attovia-logo.jpg
Attovia Therapeutics Appoints Chief Financial Officer
15 oct. 2024 07h30 HE | Attovia Therapeutics, Inc.
FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...
Attovia-logo.jpg
Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
09 juil. 2024 07h30 HE | Attovia Therapeutics, Inc.
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of...
Attovia-logo.jpg
Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives
09 mai 2024 07h30 HE | Attovia Therapeutics, Inc.
-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
Attovia-logo.jpg
Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards
26 mars 2024 07h00 HE | Attovia Therapeutics, Inc.
-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia’s Clinical and Scientific...
Attovia-logo.jpg
Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform
08 févr. 2024 07h30 HE | Attovia Therapeutics, Inc.
-- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform -- Attovia’s lead programs include...
Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 ...